Biologics Development and Manufacturing
Since 2012
High throughput technologies in USP, DSP and
Best Biologics CMO of the year in South Asia
Kemwell is an integrated biologics CDMO supporting
drug substance and drug product
Kemwell is a biologics contract development and manufacturing organisation (CDMO) providing services to global pharmaceutical and biotech organizations. Our facilities are designed and developed with technological support from a leading German biopharmaceutical company
Drug Substance and Drug Product from same site
Monoclonal antibodies, complex fusion proteins, recombinant proteins and bispecific antibodies
Licensed to manufacture commercial DS
SS and SUB with flexibility of scale
Drug Substance and Drug Product from same site
Monoclonal antibodies, complex fusion proteins, recombinant proteins and bispecific antibodies
Licensed to manufacture commercial DS
SS and SUB with flexibility of scale
Kemwell provides integrated development and manufacturing services for companies that require one-stop solution for mammalian cell-culture based protein therapeutics – monoclonal antibody, bi-specific or multi-specific antibodies, fusion proteins, etc.
Kemwell assures flexible and quick turnarounds that increase speed to clinic, experience in
supplying and supporting US IND trials (including Phase III batch manufacturing).
DS+DP COMMERCIAL BATCH MANUFACTURING OTIF>95% BATCH FAILURE <5%
IN COUNTRIES LIKE CIS,
SOUTH EAST ASIA, MENA
BY BIG PHARMA COMPANIES, QPs, Ex FDA AUDITORS
FUSION PROTEINS, BISPECIFICS AND mAbs
In an exclusive interview with The CSR Journal, Karan Bagaria talks about the…
The CDMO sector has grown and innovated immensely...
The company has acquired an Ambr 250, added three single use...